US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.6300

-0.0050-0.79%

Post-market: 0.63900.0090+1.43%19:56 EDT

Volume:449.80K

Turnover:300.53K

Market Cap:2.21M

PE:-0.02

High:0.7321

Open:0.6410

Low:0.6290

Close:0.6350

52wk High:60.00

52wk Low:0.6253

Shares:3.50M

Float Shares:1.25M

Volume Ratio:1.17

T/O Rate:35.98%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-32.4560

EPS(LYR):-371.2241

ROE:-126.98%

ROA:-62.31%

PB:0.22

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma - to Accelerate Phase 1B First-in-Human Study in Pancreatic Cancer

THOMSON REUTERS

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

THOMSON REUTERS

Propanc Biopharma Files Draft Information Statement on Restricted Stock Issuances

Propanc Biopharma Names Carlo Campiciano to Board After Van Broekhoven Retirement

Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b Trial Delivery

Propanc Biopharma - Mou to Support Phase 1B First-in-human Trial for Propanc's Prp

THOMSON REUTERS

Propanc Biopharma Signs Mou with Avance Clinical Pty Ltd

THOMSON REUTERS

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

THOMSON REUTERS

Propanc CEO visits European manufacturer ahead of drug production plan

Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study

Top Midday Gainers

MT Newswires Live

Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump

MT Newswires Live

Propanc Biopharma launches USD 5 million share buyback program

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

THOMSON REUTERS

Top Premarket Gainers

MT Newswires Live

Propanc Biopharma CEO attends University of Granada keynote on rejuvenation science

Propanc Biopharma plans Phase 1b first-in-human PRP trial in Australia in 2026

Propanc Biopharma Inc - to File Cta in Australia for Phase 1B Study in 30–40 Advanced Cancer Patients

THOMSON REUTERS

Propanc Biopharma Inc - Plans Two Phase 2 Studies in Pancreatic and Ovarian Cancers With 60 Patients Each

THOMSON REUTERS

Propanc Biopharma engages European CDMO for GMP production of PRP therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/PPCB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.63,"timestamp":1789675200000,"preClose":0.635,"halted":0,"volume":449802,"hourTrading":{"tag":"盘后","latestPrice":0.639,"preClose":0.63,"latestTime":"19:56 EDT","volume":20298,"amount":13023.9805,"timestamp":1789689366726,"change":0.009,"changeRate":0.014286,"amplitude":0.031905},"delay":0,"changeRate":-0.007874015748031503,"floatShares":1250100,"shares":3503100,"eps":-32.455997,"marketStatus":"Closed","change":-0.005,"latestTime":"09-17 16:00:00 EDT","open":0.641,"high":0.7321,"low":0.629,"amount":300525.02278272,"amplitude":0.162362,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-32.455997,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.635,"preHourTrading":{"tag":"盘前","latestPrice":0.6649,"preClose":0.635,"latestTime":"09:26 EDT","volume":38629,"amount":26696.7916175,"timestamp":1789651601668,"change":0.0299,"changeRate":0.047087,"amplitude":0.165354},"postHourTrading":{"tag":"盘后","latestPrice":0.639,"preClose":0.63,"latestTime":"19:56 EDT","volume":20298,"amount":13023.9805,"timestamp":1789689366726,"change":0.009,"changeRate":0.014286,"amplitude":0.031905},"volumeRatio":1.170156},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250100,"roa":"-62.31%","roe":"-126.98%","lyrEps":-371.224075,"volumeRatio":1.170156,"shares":3503100,"dividePrice":0,"high":0.7321,"amplitude":0.162362,"preClose":0.635,"low":0.629,"week52Low":0.6253,"pbRate":"0.22","week52High":60,"institutionHeld":0,"latestPrice":0.63,"eps":-32.455997,"divideRate":0,"volume":449802,"delay":0,"ttmEps":-32.455997,"open":0.641,"prevYearClose":13.415,"prevWeekClose":0.921,"prevMonthClose":1.35,"prevQuarterClose":1.5,"fiveDayClose":0.9428,"twentyDayClose":1.14,"sixtyDayClose":1.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-09-16","current":-0.019411,"percent":0.562044,"low":-1.336323,"twenty":-0.269509,"median":-0.125329,"eighty":-0.041422,"high":-0.023125,"avg":-0.180477,"sd":0.190159,"marketCap":1868264},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767},{"date":"2026-09-04","current":-0.12657,"twenty":-0.273833,"median":-0.12719,"eighty":-0.041245,"marketCap":2323938},{"date":"2026-09-11","current":-0.11699,"twenty":-0.269509,"median":-0.12657,"eighty":-0.041322,"marketCap":2148048},{"date":"2026-09-16","current":-0.101752,"twenty":-0.269509,"median":-0.125329,"eighty":-0.041422,"marketCap":1868264}],"updateTime":1789692206020},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657313516","title":"Propanc Biopharma - to Accelerate Phase 1B First-in-Human Study in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657313516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657313516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657440135","title":"Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2657440135","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657440135?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:30","pubTimestamp":1785933000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA9YSQLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510441","title":"Propanc Biopharma Files Draft Information Statement on Restricted Stock Issuances","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510441","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510441?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:00","pubTimestamp":1785924059,"startTime":"0","endTime":"0","summary":"Propanc Biopharma files draft information statement on restricted stock issuancesPropanc Biopharma shareholders authorized new restricted common stock issuances totaling 3.5 million shares for officer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4bhhmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651486063","title":"Propanc Biopharma Names Carlo Campiciano to Board After Van Broekhoven Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2651486063","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651486063?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:02","pubTimestamp":1784059336,"startTime":"0","endTime":"0","summary":"Propanc Biopharma names Carlo Campiciano to board after Van Broekhoven retirementPropanc Biopharma reported a board change effective July 8, 2026, with director Annie Van Broekhoven retiring and stepp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLX4K6t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7094","PPCB","BK4139","AHE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649980618","title":"Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b Trial Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980618","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980618?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:33","pubTimestamp":1783427581,"startTime":"0","endTime":"0","summary":"Propanc Biopharma signs MOU with Avance Clinical for PRP Phase 1b trial deliveryPropanc Biopharma signed an MOU with Avance Clinical to support clinical delivery of its Phase 1b first-in-human trial o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL7HSY8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","PPCB","BK4139","SG9999014039.USD","NDAQ","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014013.SGD","BCDF","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","SG9999014021.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987716","title":"Propanc Biopharma - Mou to Support Phase 1B First-in-human Trial for Propanc's Prp","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987716?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA4WFN1F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649877469","title":"Propanc Biopharma Signs Mou with Avance Clinical Pty Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2649877469","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649877469?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA4WFN1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648507485","title":"Propanc Biopharma Initiates $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648507485","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648507485?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA8RDFQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643768348","title":"Propanc CEO visits European manufacturer ahead of drug production plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643768348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643768348?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:41","pubTimestamp":1781617271,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that CEO James Nathanielsz toured a European contract development and manufacturing organization’s facility in p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-ceo-visits-european-manufacturer-ahead-of-drug-production-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-ceo-visits-european-manufacturer-ahead-of-drug-production-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","EPV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757305","title":"Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757305","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757305?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:45","pubTimestamp":1781613920,"startTime":"0","endTime":"0","summary":"Propanc Biopharma CEO James Nathanielsz toured a European CDMO’s GMP facility to prepare for PRP production tied to its Phase 1b first-in-human study.Propanc aligned project timelines with the manufacturer, targeting preproduction in August 2026, an engineering run in October 2026, GMP manufacture from December 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL33tlpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","NDAQ","IE00BN0W2W23.USD","SG9999014021.USD","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642366802","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2642366802","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642366802?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:37","pubTimestamp":1781199431,"startTime":"0","endTime":"0","summary":"Propanc Biopharma  approved a share repurchase program to buy back up to $5 million of common stock, the company said Thursday.Shares soared 124% as intraday trading volume catapulted to over 155.6 million from a daily average of about 130,000.Adial Pharmaceuticals  said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Shares soared 30% amid a surge in intraday trading volume to over 16.5 million from a daily average of roughly 118,000.Applied Materials  expanded manufacturing and research & development operations in Singapore with a $500 million facility in Tampines to support AI-driven semiconductor demand.Shares jumped 8.5% following an increase in intraday trading volume to over 5.3 million from a daily average of about 7 million.Price: 3.04, Change: +1.69, Percent Change: +124.81","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0942090050.USD","LU1069344957.HKD","LU1778281490.HKD","LU1674673691.USD","LU1721428933.USD","LU2089985449.USD","BK4518","IE0009356076.USD","LU2111349929.HKD","LU1267930813.SGD","LU2458330169.SGD","ADIL","LU0444971666.USD","BK4585","LU1989763005.USD","LU1989773731.SGD","LU1917777945.USD","LU1003077747.HKD","LU0061475181.USD","LU2028103732.USD","BK4567","LU1674673428.USD","LU0354030511.USD","IE00BSNM7G36.USD","BK4588","LU1868836757.USD","LU2413666426.HKD","LU1868837136.USD","LU1823568750.SGD","AMAT","SG9999002232.USD","LU1815333072.USD","LU0158827948.USD","LU0661504455.SGD","LU2089284900.SGD","LU0738911758.USD","LU1046421795.USD","PPCB","LU0096362180.USD","LU2413666699.HKD","LU1868836591.USD","BK4533","LU0868494708.USD","LU2458330243.SGD","BK4147","LU0957808578.USD","LU0198837287.USD","LU0175139822.USD","IE00BD6J9T35.USD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280969","title":"Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280969","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280969?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:07","pubTimestamp":1781186851,"startTime":"0","endTime":"0","summary":"Propanc Biopharma  said Thursday it approved a share repurchase program allowing it to buy back up to $5 million of its common stock.Under the program, Propanc Biopharma may repurchase shares from time to time in amounts, at prices and at times it deems appropriate, subject to market conditions, the company said.Propanc said the company \"is entering a transformative stage with a novel, first-in-class cancer therapy for treatment & prevention of metastatic cancer from solid tumors.\"Propanc Biopharma shares were more than 250% higher in Thursday trading.Price: 5.33, Change: +3.98, Percent Change: +294.81","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642849442","title":"Propanc Biopharma launches USD 5 million share buyback program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642849442","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642849442?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:31","pubTimestamp":1781181100,"startTime":"0","endTime":"0","summary":"Propanc Biopharma authorized a share repurchase program of up to USD 5 million of common stock.Buybacks may be executed from time to time, depending on market conditions, with no required minimum share count.The program can be modified, suspended, or terminated at any time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL4F7gyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4112","IE00B3QW5Z07.USD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","PPCB","BK4139","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284645","title":"Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284645","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284645?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:30","pubTimestamp":1781181000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA9604P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286454","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286454","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286454?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175643,"startTime":"0","endTime":"0","summary":"Galaxy Payroll Group  shares were up 324% in Thursday premarket activity, recovering from a 5.2% loss in the earlier session.CCH  stock was 148% higher following a largely muted Wednesday session.Propanc Biopharma  shares were up 132%, reversing from a 2.2% loss in the previous session.UTime  stock was 73% higher, following a muted Wednesday session.Quhuo  shares were up 68%, recovering from a 5% decline in the earlier session.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QH","BK4137","PPCB","WTO","BK4130","BK4139","GLXG","BK4209","BK4145","CCHH","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640199489","title":"Propanc Biopharma CEO attends University of Granada keynote on rejuvenation science","url":"https://stock-news.laohu8.com/highlight/detail?id=2640199489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640199489?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:30","pubTimestamp":1780392616,"startTime":"0","endTime":"0","summary":"Propanc CEO James Nathanielsz attended a University of Granada keynote on rejuvenation science in Granada, Spain.He highlighted Propanc’s proenzyme research with Granada and Jaén universities as PRP targets a Phase 1b first-in-human trial in advanced cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL5YzzDn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","BK4588","SG9999014021.USD","IE00BN0W2V16.EUR","BK4112","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","PPCB","NDAQ","BK4139","IE00B64PRP62.GBP","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636784703","title":"Propanc Biopharma plans Phase 1b first-in-human PRP trial in Australia in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636784703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636784703?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:04","pubTimestamp":1779282277,"startTime":"0","endTime":"0","summary":"Propanc Biopharma on May 20, 2026 outlined plans to start a first-in-human Phase 1b study of its PRP drug candidate in 30-40 advanced solid-tumor patients later this year, with results to be presented in the future.The trial is designed to assess safety and tolerability for a higher-dose, once-weekly intravenous formulation, marking a shift from earlier compassionate-use dosing.Prior compassionate-use findings were already published, with patients exceeding expected survival and no severe side effects reported.The company expects Phase 1b to support subsequent Phase 2 studies in pancreatic cancer and ovarian cancer to test whether PRP can show clinical benefit in those settings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL49cDQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847826","title":"Propanc Biopharma Inc - to File Cta in Australia for Phase 1B Study in 30–40 Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636847826?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:45","pubTimestamp":1779281151,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636829847","title":"Propanc Biopharma Inc - Plans Two Phase 2 Studies in Pancreatic and Ovarian Cancers With 60 Patients Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2636829847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636829847?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:45","pubTimestamp":1779281151,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636593859","title":"Propanc Biopharma engages European CDMO for GMP production of PRP therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636593859","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636593859?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:45","pubTimestamp":1779194716,"startTime":"0","endTime":"0","summary":"Propanc Biopharma engaged a Europe-based contract development and manufacturing organization to produce GMP-grade PRP for a planned Phase 1b first-in-human trial.Manufacturing is intended to support a 30-40 patient study in advanced solid-tumor cancers, with a clinical trial application targeted for filing later this year.PRP is designed for once-weekly intravenous dosing, with the study expected to test significantly higher doses than prior compassionate-use experience cited by the company.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3bwKYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","BK4585","IE00BKPKM429.USD","PPCB","SG9999014039.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4588","LU2210149790.SGD","BK4112","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}]}}